[1. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C: an update. [Practice Guideline.] Hepatology 2009; 49: 1335-74.10.1002/hep.22759]Search in Google Scholar
[2. Kanwal F, Hoang T, Kramer JR et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011; 140: 1182-8.10.1053/j.gastro.2010.12.032]Search in Google Scholar
[3. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004; 24(Suppl 2): 3-8.10.1055/s-2004-832922]Search in Google Scholar
[4. Pradat P, Tillmann HL, Sauleda S et al. Long-term follow- up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat 2007; 14: 556-63.10.1111/j.1365-2893.2006.00829.x]Search in Google Scholar
[5. Namazee N, Sali S, Asadi S, Shafiei M, Behnava B, Alavian SM. Real Response to Therapy in Chronic Hepatitis C Virus Patients: A Study From Iran. Hepat Mon 2012; 12(9): e6151.10.5812/hepatmon.6151]Search in Google Scholar
[6. Navaneethan U, Kemmer N and Neff GW. Predicting the probable outcome of treatment in HCV patients. Ther Adv Gastroenterol 2009; 2(5): 287-302.10.1177/1756283X09339079]Search in Google Scholar
[7. Manns MP, Wedemeyer H and Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55: 1350-9.10.1136/gut.2005.076646]Search in Google Scholar
[8. Pawlowska M, Pilarczyk M, Foksinska A, Smukalska E, Halota W. Hematological Adverse events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C Infection. Hepat Mon 2011; 11(12): 968-74.10.5812/kowsar.1735143X.4223]Search in Google Scholar
[9. Feuerstadt P, Bunim AL, Garcia H et al. Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. Hepatology 2010; 51(4): 1137-43.10.1002/hep.23429]Search in Google Scholar
[10. Berg T, Sarrazin C, Herrmann E et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37(3): 600-9.10.1053/jhep.2003.50106]Search in Google Scholar
[11. Pozzato G, Moretti M, Crocé LS et al. Interferon therapy in chronic hepatitis C virus: evidence of different outcome with respect to different viral strains. J Med Virol 1995; 45(4): 445-50.10.1002/jmv.1890450416]Search in Google Scholar
[12. Ghany MG, Strader DB, Thomas DL et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49(4): 1335-74.10.1002/hep.22759]Search in Google Scholar
[13. Karino Y, Toyota J, Sugawara M et al. Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C. J Gastroenterol Hepatol 2003; 18(4): 404-10.10.1046/j.1440-1746.2003.03009.x]Search in Google Scholar
[14. Vuković VR, Baskić D, Mijailović Ž, Đurđević P, Jovanović D, Mitrović S and Popović S. Association between risk factors, basal viral load, virus genotype and the degree of liver fibrosis with the response to therapy in patients with chronic HCV infection. Vojnosanit Pregl 2015; June vol. 72 (No. 6): pp. (in press).10.2298/VSP1506505V]Search in Google Scholar
[15. Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alfa-2a in patients with chronic Hepatitis C. N Engl J Med 2000; 343(23): 1666-72.10.1056/NEJM200012073432301]Search in Google Scholar
[16. Gordon SC, Fang JW, Silverman AL, McHutchison JG, Albrecht JK. The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C. Hepatology 2000; 32(2): 400-4.10.1053/jhep.2000.9321]Search in Google Scholar
[17. Sulkowski MS, Wasserman R, Brooks L et al. Changes in hemoglobin during interferon alfa-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004; 11: 243-50.10.1111/j.1365-2893.2004.00490.x]Search in Google Scholar
[18. Sulkowski M. Management of the hematologic complications of hepatitis C therapy. Clin Liver Dis 2005; 9: 601-16.10.1016/j.cld.2005.07.007]Search in Google Scholar
[19. Soza A, Everhart JE, Ghany MG et al. Neutropenia during combination therapy of interferon alpha and ribavirin for chronic hepatitis C. Hepatology 2002; 36: 1273-9.10.1053/jhep.2002.36502]Search in Google Scholar
[20. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35: 1002-9.10.1053/jhep.2002.32672]Search in Google Scholar
[21. Lu M, Zhang W, Li Y et al. Interferon-α targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp Hematol 2010; 38(6):472-80.10.1016/j.exphem.2010.03.005]Search in Google Scholar
[22. Chott A, Gisslinger H, Thiele J et al. Interferon-alphainduced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis. Brit J Haematol 1990; 74(1): 10-6.10.1111/j.1365-2141.1990.tb02531.x]Search in Google Scholar
[23. Sulkowski M, Shiffman M, Afdhal N et al. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology 2010; 139(5): 1602-11.10.1053/j.gastro.2010.07.059]Search in Google Scholar
[24. Sievert W, Dore GJ, McCaughan GW et al; CHARIOT Study Group. Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Hepatology 2011; 53(4): 1109-17.10.1002/hep.24180]Search in Google Scholar
[25. Suwantarat N, Tice AD, Khawcharoenporn T, Chow DC. Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to Hepatitis C treatment. Int J Med Sci 2010; 7(1): 36-42.10.7150/ijms.7.36]Search in Google Scholar
